1. Home
  2. GKOS vs CHSCN Comparison

GKOS vs CHSCN Comparison

Compare GKOS & CHSCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$112.02

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Logo CHS Inc Preferred Class B Series 2 Reset Rate

CHSCN

CHS Inc Preferred Class B Series 2 Reset Rate

HOLD

Current Price

$25.15

Market Cap

0.0

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
CHSCN
Founded
1998
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Farming/Seeds/Milling
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
N/A
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
CHSCN
Price
$112.02
$25.15
Analyst Decision
Strong Buy
Analyst Count
14
0
Target Price
$127.71
N/A
AVG Volume (30 Days)
647.7K
N/A
Earning Date
02-19-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$469,820,000.00
N/A
Revenue This Year
$31.15
N/A
Revenue Next Year
$24.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.38
N/A
52 Week Low
$73.16
N/A
52 Week High
$163.71
N/A

Technical Indicators

Market Signals
Indicator
GKOS
CHSCN
Relative Strength Index (RSI) 57.92 56.43
Support Level $110.46 $24.83
Resistance Level $117.94 $25.28
Average True Range (ATR) 2.92 0.18
MACD -1.15 0.03
Stochastic Oscillator 35.93 81.48

Price Performance

Historical Comparison
GKOS
CHSCN

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About CHSCN CHS Inc Preferred Class B Series 2 Reset Rate

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

Share on Social Networks: